On October 1, 2025 Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, reported the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer ("CFO"), effective immediately (Press release, Immatics, OCT 1, 2025, View Source [SID1234656378]). Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep financial expertise in facilitating successful product launches, establishing scalable operations in global markets and enabling corporate transactions. He joins Immatics from Anthos Therapeutics, a Novartis company, where he served as CFO. He will succeed Immatics’ current CFO, Arnd Christ.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are thrilled to welcome Venkat to Immatics as an accomplished and passionate biopharmaceutical leader. His extensive experience will be instrumental in enabling us to continue to advance our PRAME franchise as well as rapidly move our PRAME cell therapy, anzu-cel, toward commercialization and to patients with a significant unmet medical need," said Harpreet Singh, Ph.D., Chief Executive Officer and Co-Founder of Immatics. "I would also like to extend our gratitude to Arnd Christ for his financial leadership and tremendous contributions that have brought Immatics to where it stands today. On behalf of the entire team, I wish him all the best in his future endeavors."
"This is a pivotal moment to join Immatics as the company advances toward its first commercial launch and works to bring its innovative PRAME cell therapy, anzu-cel, to patients with metastatic melanoma," said Venkat Ramanan, Ph.D., Chief Financial Officer of Immatics. "I look forward to collaborating closely with the team during this dynamic stage of growth and supporting the transition to a commercial-stage organization. Together, we will further strengthen Immatics’ position as the global leader in precision targeting of PRAME, united by our commitment to making a meaningful impact on the lives of patients with cancer."
Dr. Ramanan brings more than 25 years of experience and leadership in finance, strategy and operations across large and small biopharmaceutical companies, with a proven track record of leading companies through periods of successful transformation and growth. He joins Immatics from Anthos Therapeutics, a clinical-stage biotechnology company acquired by Novartis in April 2025, where he served as CFO. Previously, he was CFO at Turnstone Biologics, where he led the company’s transition from a private to public company through its IPO. Earlier, as Senior Vice President Finance at Seagen, he oversaw the finance department enabling multiple product launches, global expansion and strategic transactions. He also held senior finance and business leadership roles at Gilead Sciences and Amgen. He began his career in the biopharmaceutical industry as a consultant with ZS Associates. Dr. Ramanan holds a Ph.D. in Engineering Mechanics from The Ohio State University.